HIV-Associated Comorbidities



This chapter will review common noninfectious and infectious comorbidities that place patients at risk of polypharmacy and associated pharmacokinetic and pharmacodynamic drug interactions with antiretroviral agents.


Mental Health Disorder Immune Reconstitution Inflammatory Syndrome Drug Interaction Potential Subsequent Chapter Receive Protease Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H et al (2010) Prevalence of comedications and effect of potential drug-drug interactions in the Swisss HIV Cohort Study. Antivir Ther 15(3):413–423CrossRefPubMedGoogle Scholar
  2. 2.
    World Health Organization (WHO). Chapter 8: Clinical guidance across the continuum of care: managing common coinfections and comorbidities. In: Consolidated ARV guidelines. 2013. Available from: Accessed 18 June 2016
  3. 3.
    Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M et al (2007) Do patters of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 45(12):1593–1601CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M (2005) Tuberculosis control in the era of HIV. Nat Rev Immunol 5(10):819–826CrossRefPubMedGoogle Scholar
  5. 5.
    World Health Organization (WHO) (2010) Treatment of tuberculosis guidelines, 4th ed. Available from: Accessed 18 June 2016
  6. 6.
    Horne DJ, Spitters C, Narita M (2011) Experience with rifabutin replacing rifampin in the treatemnt of tuberculosis. Int J Tuberc Lung Dis 15(11):1485–1489CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 2016. Available at Accessed 15 June 2016
  8. 8.
    Centers for Disease Control and Prevention (CDC). Recommendations for the use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR. Morbidity and mortality weekly reports 2011;60:1650–1653. Available from: Accessed 19 June 2016
  9. 9.
    World Health Organization (WHO) (2015) Guidelines for the treatment of malaria, 3rd ed. Available from: Accessed 18 June 2016
  10. 10.
    Kiang TK, Wilby KJ, Ensom MH (2014) Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals. Clin Pharmacokinet 53(2):141–153CrossRefPubMedGoogle Scholar
  11. 11.
    Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44(1Suppl):S6–S9CrossRefPubMedGoogle Scholar
  12. 12.
    Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F et al (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22(12):1399–1410CrossRefPubMedGoogle Scholar
  13. 13.
    El-Sherif O, Back D (2015) Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person. Curr HIV/AIDS Rep 12(3):336–343CrossRefPubMedGoogle Scholar
  14. 14.
    Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL (2000) Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 19(2):124–133CrossRefPubMedGoogle Scholar
  15. 15.
    Mojtabai R, Olfson M (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67(1):26–36CrossRefPubMedGoogle Scholar
  16. 16.
    Gruber VA, McCance-Katz EF (2010) Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep 7(3):152–160CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    DeSilva KE, Le Flore DB, Marston BJ, Rimland D (2001) Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 15(10):1281–1285CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2016

Authors and Affiliations

  1. 1.College of PharmacyQatar UniversityDohaQatar
  2. 2.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada

Personalised recommendations